

Rheumatology Patients on Biologic Treatments and Covid-19

Rheumatology patients on biologic treatments prescribed by the secondary care team, either as monotherapy or in combination with conventional Disease Modifying anti-rheumatic drugs, should be classed as clinically vulnerable and fall into priority group 6 for the COVID vaccine, if not in a higher group for other reasons.

Biologic drugs include:

- abatacept (orencia)
- adalimumab (humira, imraldi, amgevita)
- anakinra (kineret)
- baricitimib (olimiant)
- certolizumab pegol (cimzia)
- etanercept (benepali, Enbrel)
- golimumab (simponi)
- infliximab (remicade, remsine, inflectra)
- ixekizumab (taltz)
- rituximab (mabthera, rixathon)
- sarilumab (keczara)
- secukinumab (cosentyx)
- tocilizumab (roactemra)
- tofacitinib (xeljanz)
- Upadacitinib (rinvoq)
- Ustekinumab (stelara)